Patents by Inventor Wenjing XIA

Wenjing XIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250179212
    Abstract: The present invention provides methods of treating cancer by modulating regulators of IL-33. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with agents that modulate FOX1A. Also provided are diagnostic methods for assessing cancer prognosis.
    Type: Application
    Filed: January 9, 2023
    Publication date: June 5, 2025
    Inventors: Wilfred A. Jefferies, Wenjing Xia
  • Patent number: 10800776
    Abstract: A fluorine-containing triazolopyridine represented by formula (I) and a racemate, R-stereoisomer, S-stereoisomer, pharmaceutically acceptable salt, or mixture thereof are described. The triazolopyridine can be used as a positive allosteric modulator of an mGluR2, and is highly selective in activating the mGluR2, exerting no activation or very limited activation of other homologous metabotropic glutamate receptor. The triazolopyridine can thus be used to prepare a product for treating an mGluR2-related disease, such as a central nervous system disease or neurological disease.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: October 13, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Yu Zhou, Wenjing Xia, Dong Zhang, Hualiang Jiang, Kaixian Chen
  • Publication number: 20190202827
    Abstract: A fluorine-containing triazolopyridine represented by formula (I) and a racemate, R-stereoisomer, S-stereoisomer, pharmaceutically acceptable salt, or mixture thereof are described. The triazolopyridine can be used as a positive allosteric modulator of an mGluR2, and is highly selective in activating the mGluR2, exerting no activation or very limited activation of other homologous metabotropic glutamate receptor. The triazolopyridine can thus be used to prepare a product for treating an mGluR2-related disease, such as a central nervous system disease or neurological disease.
    Type: Application
    Filed: May 17, 2017
    Publication date: July 4, 2019
    Inventors: Hong LIU, Yu ZHOU, Wenjing XIA, Dong ZHANG, Hualiang JIANG, Kaixian CHEN